Recap: Badger Meter Q4 Earnings

  Badger Meter (NYSE:BMI) reported its Q4 earnings results on Friday, January 28, 2022 at 08:30 AM. Here's what investors need to know about the announcement.

 

Badger Meter (NYSE:BMI) reported its Q4 earnings results on Friday, January 28, 2022 at 08:30 AM.

Here’s what investors need to know about the announcement.

Earnings

Badger Meter beat estimated earnings by 25.53%, reporting an EPS of $0.59 versus an estimate of $0.47, which surprised analysts.

Revenue was up $23.42 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.04, which was followed by a 0.74% increase in the share price the next day.

Here’s a look at Badger Meter’s past performance:

 

Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020
EPS Estimate 0.50 0.46 0.42 0.43
EPS Actual 0.54 0.48 0.47 0.45
Revenue Estimate 126.47M 118.35M 120.40M 109.15M
Revenue Actual 128.74M 122.87M 117.84M 112.33M

To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

NGM Bio Presents Updated Preliminary Findings From Ongoing Phase 1b Dose Escalation Trial Of NGM120 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Cancer At AACR Special Conference: Pancreatic Cancer

NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancer NGM120 has been well tolerated to date in patients in the Phase 1b combination cohort (NGM120 +

NGM